US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.

Most generics and biosimilars in the US contain ingredients made elsewhere or are produced entirely abroad, which will hit consumers immediately, Richard Saynor, the chief executive officer of Sandoz Group AG, said in an interview with Bloomberg TV.

“In the short term I think it will drive even more patient-access instability,” he said. In the medium term, pricing increases will be passed on to payers and ultimately to patients, ...